🇺🇸 FDA
Pipeline program

MITAPIVAT

AG348-C-026

Phase 2 small_molecule active

Quick answer

MITAPIVAT for Sickle Cell Disease (SCD) and Nephropathy is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Sickle Cell Disease (SCD) and Nephropathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials